JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial

30
Female doctor holding a pill, medical treatment, drugs and healthcare concept

(Reuters) – Johnson and Johnson said on Tuesday a combination therapy containing its blockbuster cancer drug Imbruvica significantly improved survival in blood cancer patients, compared with drugs currently used as the standard of care.

In the study, Imbruvica, jointly sold with AbbVie Inc, was given to newly diagnosed chronic lymphocytic leukemia (CLL) patients aged 70 or younger, in combination with Roche AG’s Rituxan.

The combination was tested against Rituxan administered with chemotherapy drugs fludarabine and cyclophosphamide, and patients showed a 65 percent reduction in risk of disease progression or death, AbbVie said in a statement.

 

More https://www.reuters.com/article/us-johnson-johnson-imbruvica/jnj-abbvie-cancer-drug-imbruvica-succeeds-in-late-stage-trial-idUSKBN1O31ZW